| Year |
Citation |
Score |
| 2023 |
Rai R, Dey DK, Benbrook DM, Chandra V. Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 161: 114422. PMID 36841028 DOI: 10.1016/j.biopha.2023.114422 |
0.389 |
|
| 2022 |
Rai R, Chandra V, Kennedy AL, Zuna RE, Benbrook DM. Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Frontiers in Oncology. 12: 958536. PMID 36203464 DOI: 10.3389/fonc.2022.958536 |
0.353 |
|
| 2022 |
Benbrook DM. SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. Frontiers in Cell and Developmental Biology. 10: 848682. PMID 35281109 DOI: 10.3389/fcell.2022.848682 |
0.31 |
|
| 2021 |
Chandra V, Rai R, Benbrook DM. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. Cancers. 13. PMID 34066052 DOI: 10.3390/cancers13102322 |
0.386 |
|
| 2020 |
Rai R, Essel KG, Benbrook DM, Garland J, Zhao YD, Chandra V. Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. Cancers. 12: 1273. PMID 32443471 DOI: 10.3390/Cancers12051273 |
0.48 |
|
| 2020 |
Kennedy AL, Rai R, Isingizwe ZR, Zhao YD, Lightfoot SA, Benbrook DM. Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. Cancers. 12. PMID 32429557 DOI: 10.3390/Cancers12051269 |
0.401 |
|
| 2020 |
Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. The Aaps Journal. 22: 51. PMID 32086622 DOI: 10.1208/S12248-020-0421-Z |
0.351 |
|
| 2020 |
Isingizwe ZR, Benbrook DM. Abstract 2840: Development of a model of dihomo-gamma-linolenic acid interference with platelet promotion of ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-2840 |
0.336 |
|
| 2020 |
Vaughn K, Lausen J, Bruns M, Benbrook D, Hannafon B. A novel drug inhibits exosome content loading and secretion in ovarian cancer cells The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04409 |
0.385 |
|
| 2020 |
Essel K, Benbrook D, Rai R, Chandra V. Sulforaphane as a Potential Therapeutic for Endometrial Cancer Gynecologic Oncology. 156: e30. DOI: 10.1016/J.Ygyno.2019.11.092 |
0.386 |
|
| 2019 |
Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53. International Journal of Cancer. PMID 31845320 DOI: 10.1002/Ijc.32830 |
0.415 |
|
| 2019 |
Gnanasekaran KK, Pouland T, Bunce RA, Darrell Berlin K, Abuskhuna S, Bhandari D, Mashayekhi M, Zhou DH, Benbrook DM. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorganic & Medicinal Chemistry. 115244. PMID 31831296 DOI: 10.1016/J.Bmc.2019.115244 |
0.319 |
|
| 2019 |
Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. European Journal of Medicinal Chemistry. 170: 16-27. PMID 30878829 DOI: 10.1016/J.Ejmech.2019.03.010 |
0.388 |
|
| 2019 |
Ramraj SK, Benbrook DM. Abstract NT-104: SYNERGISTIC COMBINATION OF MORTALIN-TARGETING AND P53 REACTIVATOR DRUGS FOR OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-104 |
0.428 |
|
| 2019 |
Ramraj SK, Isingizwe ZR, Elayapillai SP, Bosley AL, Zhao YD, Benbrook DM. Abstract LB-244: Prevention of ovarian cancer tumor establishment with mortalin targeting and p53 reactivator drugs Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-244 |
0.433 |
|
| 2019 |
Elayapillai SP, Ramraj SK, Benbrook DM, Gunderson CC. Abstract 4652: Repurposing mebendazole in combination with PRIMA1METfor ovarian cancer therapy Cancer Research. 79: 4652-4652. DOI: 10.1158/1538-7445.Am2019-4652 |
0.409 |
|
| 2019 |
Dockery LE, Ward JM, Vesely SK, Thavathiru E, Benbrook DM, Moore KN, Holman LL. Vitamin D, leptin, vitamin D receptor single nucleotide polymorphism and treatment-related morbidity in ovarian, primary peritoneal, and fallopian tube cancer Gynecologic Oncology. 154. DOI: 10.1016/J.Ygyno.2019.03.218 |
0.311 |
|
| 2018 |
Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Letters. PMID 29574275 DOI: 10.1016/J.Canlet.2018.03.027 |
0.383 |
|
| 2017 |
Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs. PMID 29273857 DOI: 10.1007/S10637-017-0550-0 |
0.741 |
|
| 2017 |
Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch A, Lang ML, Rao CV. Loss of natural killer T (NKT) cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. Immunology. PMID 28419443 DOI: 10.1111/Imm.12746 |
0.37 |
|
| 2017 |
Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncology Reports. 37: 2382-2390. PMID 28260023 DOI: 10.3892/Or.2017.5478 |
0.401 |
|
| 2017 |
Chandra V, Long A, Masamha CP, Benbrook DM. Abstract 3308: Mitophagy induction and interference with cancer-specific apoptosis in SHetA2-treated cells Cancer Research. 77: 3308-3308. DOI: 10.1158/1538-7445.Am2017-3308 |
0.786 |
|
| 2017 |
Ramraj SK, Pelikan R, Chandra V, Benbrook D. Abstract 3225: SHetA2 targets mortalin-p53 interaction in differential induction of apoptosis in ovarian cancer over normal cells Cancer Research. 77: 3225-3225. DOI: 10.1158/1538-7445.Am2017-3225 |
0.435 |
|
| 2017 |
Thavathiru E, Chandra V, Rai R, Benbrook D. Abstract 1798: Mortalin precursor as potential marker for chemoprevention with SHetA2 Cancer Research. 77: 1798-1798. DOI: 10.1158/1538-7445.Am2017-1798 |
0.383 |
|
| 2016 |
Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S. Label-free Real-time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. Analytical Chemistry. PMID 26886845 DOI: 10.1021/Acs.Analchem.5B04234 |
0.308 |
|
| 2015 |
Okon IS, Ding Y, Coughlan KA, Wang Q, Song P, Benbrook DM, Zou MH. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. PMID 26701889 DOI: 10.18632/Oncotarget.6699 |
0.404 |
|
| 2015 |
Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic Options for Management of Endometrial Hyperplasia: An Update. Journal of Gynecologic Oncology. PMID 26463434 DOI: 10.3802/Jgo.2016.27.E8 |
0.315 |
|
| 2015 |
Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Management and Research. 7: 291-9. PMID 26392787 DOI: 10.2147/Cmar.S34859 |
0.39 |
|
| 2015 |
DiSilvestro PA, Lightfoot SA, Benbrook DM. Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression. Journal of Lower Genital Tract Disease. 3: 111-5. PMID 25950557 DOI: 10.1046/J.1526-0976.1999.08095.X |
0.338 |
|
| 2015 |
Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. European Journal of Medicinal Chemistry. 96: 209-17. PMID 25880346 DOI: 10.1016/J.Ejmech.2015.03.070 |
0.381 |
|
| 2015 |
Slaughter KN, Okon II, McMeekin S, Benbrook D, Scott B, Moore K. Expression Profiles of LKB1/AMPK in Endometrial Cancer Specimens as a Potential Biomarker for Targeted Metabolic Drug Therapy Brachytherapy. 14: 100-101. DOI: 10.1016/J.Ygyno.2014.03.322 |
0.316 |
|
| 2014 |
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 38-43. PMID 25019571 DOI: 10.1016/J.Ygyno.2014.07.083 |
0.375 |
|
| 2014 |
Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA. History of retinoic acid receptors. Sub-Cellular Biochemistry. 70: 1-20. PMID 24962878 DOI: 10.1007/978-94-017-9050-5_1 |
0.333 |
|
| 2014 |
Bishop EA, Lightfoot S, Thavathiru E, Benbrook DM. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Investigation. 32: 63-70. PMID 24499106 DOI: 10.3109/07357907.2013.877479 |
0.331 |
|
| 2014 |
Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Investigational New Drugs. 32: 412-23. PMID 24254390 DOI: 10.1007/S10637-013-0041-X |
0.398 |
|
| 2014 |
Slaughter K, Thai T, Penaroza S, Benbrook D, Thavathiro E, Ding K, McMeekin D, Moore K. Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC) Gynecologic Oncology. 133: 171. DOI: 10.1016/J.Ygyno.2014.03.451 |
0.342 |
|
| 2013 |
Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prevention Research (Philadelphia, Pa.). 6: 908-16. PMID 23852423 DOI: 10.1158/1940-6207.Capr-13-0171 |
0.638 |
|
| 2013 |
Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecologic Oncology. 130: 377-82. PMID 23632208 DOI: 10.1016/J.Ygyno.2013.04.054 |
0.332 |
|
| 2013 |
Naylor MF, Thompson DM, Lightfoot S, Benbrook DM. Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer Journal of Cancer Therapy. 4: 7-19. DOI: 10.4236/Jct.2013.46A1002 |
0.494 |
|
| 2013 |
Lightfoot S, Zhao D, Thavathiru E, Benbrook DM. Abstract 3703: SHetA2 decreases mitoses and growth, and alters pathology of MNU-induced rat mammary tumors. Cancer Research. 73: 3703-3703. DOI: 10.1158/1538-7445.Am2013-3703 |
0.329 |
|
| 2012 |
Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutation Research. 746: 78-88. PMID 22498038 DOI: 10.1016/J.Mrgentox.2012.03.009 |
0.309 |
|
| 2012 |
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo Oncogene. 31: 2725-2737. PMID 22002305 DOI: 10.1038/Onc.2011.455 |
0.46 |
|
| 2012 |
Benbrook D, Bishop E, Nugent E, Lightfoot S, Elangovan T, Long A, Zhao D. Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-P56 |
0.367 |
|
| 2011 |
Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Letters. 312: 11-7. PMID 21899946 DOI: 10.1016/J.Canlet.2011.06.032 |
0.396 |
|
| 2011 |
Benbrook DM, Masamha CP. The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Current Cancer Drug Targets. 11: 586-99. PMID 21486222 DOI: 10.2174/156800911795655994 |
0.758 |
|
| 2011 |
Ramachandran I, Reis AMC, Anant S, Queimado L, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook D, Zuna R, Lightfoot S. Abstract C21: Wnt inhibitory factor 1 is silenced by promoter hypermethylation in cervical cancer and its restoration suppresses tumor growth Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C21 |
0.437 |
|
| 2011 |
Bishop EA, Lightfoot SA, Benbrook DM. Abstract 1341: Insulin directly induces endometrial cell proliferation and carcinogenesis Cancer Research. 71: 1341-1341. DOI: 10.1158/1538-7445.Am2011-1341 |
0.326 |
|
| 2011 |
Bishop E, Lightfoot S, Benbrook D. Insulin promotes proliferation and carcinogenesis of normal endometrial cells Gynecologic Oncology. 120: S50. DOI: 10.1016/J.Ygyno.2010.12.122 |
0.304 |
|
| 2010 |
Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology. 119: 444-50. PMID 20846715 DOI: 10.1016/J.Ygyno.2010.08.002 |
0.334 |
|
| 2010 |
Zheng J, Lou JR, Zhang XX, Benbrook DM, Hanigan MH, Lind SE, Ding WQ. N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Letters. 298: 186-94. PMID 20667650 DOI: 10.1016/J.Canlet.2010.07.003 |
0.384 |
|
| 2010 |
Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anti-Cancer Drugs. 21: 297-305. PMID 20032777 DOI: 10.1097/Cad.0B013E3283350E43 |
0.764 |
|
| 2010 |
Guruswamy S, Benbrook D, Zhang Y, Qian L, Mohammed A, Rao CV. Abstract A140: Chemoprevention of familial adenomatous polyposis by a flexible‐heteroarotinoid (Flex‐Het), SHetA2, in APCMin mice Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A140 |
0.63 |
|
| 2010 |
Zheng J, Lou JR, Benbrook DM, Hanigan MH, Lind SE, Ding W. Abstract 4382: N-acetylcysteine interacts with Cu++ to induce cancer cell death through the generation of hydrogen peroxide Cancer Research. 70: 4382-4382. DOI: 10.1158/1538-7445.Am10-4382 |
0.389 |
|
| 2010 |
Moxley KM, Chengedza S, Benbrook DM. Erratum to “Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents” [Gynecol. Oncol. 115 (2009) 438–442] Gynecologic Oncology. 117: 510. DOI: 10.1016/J.Ygyno.2010.02.026 |
0.755 |
|
| 2009 |
Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecologic Oncology. 115: 438-42. PMID 19804900 DOI: 10.1016/J.Ygyno.2009.09.007 |
0.787 |
|
| 2009 |
Palwai NR, Zang XP, Harrison RG, Benbrook D, Pento JT. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 84: 271-5. PMID 19797936 DOI: 10.1159/000242997 |
0.414 |
|
| 2009 |
Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Research. 69: 6565-72. PMID 19638577 DOI: 10.1158/0008-5472.Can-09-0913 |
0.761 |
|
| 2009 |
Tuller ER, Beavers CT, Lou JR, Ihnat MA, Benbrook DM, Ding WQ. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Molecular Pharmacology. 76: 588-95. PMID 19528198 DOI: 10.1124/Mol.109.057430 |
0.422 |
|
| 2009 |
Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochemical Pharmacology. 77: 1480-6. PMID 19426685 DOI: 10.1016/J.Bcp.2009.02.002 |
0.442 |
|
| 2009 |
Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics. 8: 1227-38. PMID 19417155 DOI: 10.1158/1535-7163.Mct-08-1069 |
0.778 |
|
| 2009 |
Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs. 27: 304-18. PMID 18802666 DOI: 10.1007/S10637-008-9175-7 |
0.79 |
|
| 2008 |
Benbrook DM, Lightfoot S, Ranger-Moore J, Liu T, Chengedza S, Berry WL, Dozmorov I. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regulation and Systems Biology. 2: 21-42. PMID 19784388 DOI: 10.4137/Grsb.S344 |
0.763 |
|
| 2008 |
Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Molecular Cancer Therapeutics. 7: 3556-65. PMID 19001438 DOI: 10.1158/1535-7163.Mct-08-0648 |
0.432 |
|
| 2008 |
Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 22: 3371-81. PMID 18837006 DOI: 10.1002/Rcm.3744 |
0.301 |
|
| 2008 |
Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Research. 68: 5335-44. PMID 18593935 DOI: 10.1158/0008-5472.Can-07-6209 |
0.463 |
|
| 2008 |
Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Research. 68: 1636-46. PMID 18339842 DOI: 10.1158/0008-5472.Can-07-2345 |
0.317 |
|
| 2008 |
Masamha C, Benbrook D. Abstract A13: Chemoprevention agent SHetA2 induces G1 arrest through modulation of a biological system driven by Cyclin D1 Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-A13 |
0.765 |
|
| 2007 |
Le TC, Berlin KD, Benson SD, Eastman MA, Bell-Eunice G, Nelson AC, Benbrook DM. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. The Open Medicinal Chemistry Journal. 1: 11-23. PMID 19662136 DOI: 10.2174/1874104500701010011 |
0.386 |
|
| 2007 |
Liu T, Hannafon B, Gill L, Kelly W, Benbrook D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Molecular Cancer Therapeutics. 6: 1814-22. PMID 17575110 DOI: 10.1158/1535-7163.Mct-06-0279 |
0.43 |
|
| 2007 |
McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology. 105: 508-16. PMID 17306350 DOI: 10.1016/J.Ygyno.2007.01.019 |
0.347 |
|
| 2006 |
Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. American Journal of Pharmacology and Toxicology. 1: 83-86. PMID 19890461 DOI: 10.3844/Ajptsp.2006.83.86 |
0.451 |
|
| 2006 |
Matsuzaki S, Hayes JM, Benbrook DM, Jankowiak R. Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. The Journal of Physical Chemistry. B. 110: 16124-30. PMID 16898770 DOI: 10.1021/Jp060114I |
0.362 |
|
| 2006 |
Chiu PM, Feng HC, Benbrook DM, Ngan HY, Khoo US, Xue WC, Tsao SW, Chan KW, Cheung AN. Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. Journal of Clinical Pathology. 59: 845-50. PMID 16461808 DOI: 10.1136/Jcp.2005.025833 |
0.339 |
|
| 2006 |
Guruswamy S, Benbrook DM. Retinoids Chemosensitize Ovarian Cancer Cell Lines to Cisplatin Independent of Nuclear Receptors and p53 American Journal of Pharmacology and Toxicology. 1: 87-93. DOI: 10.3844/Ajptsp.2006.87.93 |
0.7 |
|
| 2006 |
Lu S, Benbrook DM. Role of AP-1 Antagonism in Growth Inhibition of Cervical Cancer Cell Lines by Retinoids American Journal of Pharmacology and Toxicology. 1: 40-47. DOI: 10.3844/Ajptsp.2006.40.47 |
0.647 |
|
| 2006 |
Benbrook DM. Organotypic cultures represent tumor microenvironment for drug testing Drug Discovery Today: Disease Models. 3: 143-148. DOI: 10.1016/J.Ddmod.2006.05.005 |
0.318 |
|
| 2005 |
Benbrook DM, Kamelle SA, Guruswamy SB, Lightfoot SA, Rutledge TL, Gould NS, Hannafon BN, Dunn ST, Berlin KD. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Investigational New Drugs. 23: 417-28. PMID 16133793 DOI: 10.1007/S10637-005-2901-5 |
0.696 |
|
| 2005 |
Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL, Benbrook DM. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecologic Oncology. 97: 142-50. PMID 15790450 DOI: 10.1016/J.Ygyno.2004.12.034 |
0.628 |
|
| 2005 |
Subramanian S, Smith CM, Tabatabai A, Bryan CD, Buettner B, Hale S, Wakefield CA, Benbrook DM, Berlin KD. Synthesis of novel heteroarotinoids with receptor activation capabilities and tgase activity. Single crystal analysis of (E)-4-[(2,3-dihydro-2,2,4,4,- tetramethyl-2H-1-benzo-[b]thiopyran-6-Yl)-1-propenyl]-2-methylbenzoic acid Phosphorus, Sulfur and Silicon and the Related Elements. 180: 67-77. DOI: 10.1080/104265090507678 |
0.301 |
|
| 2004 |
Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. Journal of Medicinal Chemistry. 47: 999-1007. PMID 14761202 DOI: 10.1021/Jm030346V |
0.693 |
|
| 2003 |
Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Research. 63: 3826-32. PMID 12839980 |
0.362 |
|
| 2003 |
Benbrook DM. Nature Reviews Cancer Jama: the Journal of the American Medical Association. 289: 1049-1050. DOI: 10.1001/Jama.289.8.1049 |
0.344 |
|
| 2002 |
Benbrook DM. Refining retinoids with heteroatoms Mini Reviews in Medicinal Chemistry. 2: 277-283. PMID 12370069 DOI: 10.2174/1389557023406160 |
0.328 |
|
| 2002 |
Scribner DR, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecologic Oncology. 85: 223-5. PMID 11925151 DOI: 10.1006/Gyno.2002.6590 |
0.426 |
|
| 2001 |
Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Capone F, Dusonchet L, Meli M, Raimondi MV, Landino M, D'Alessandro N, ... ... Benbrook DM, et al. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells Journal of Medicinal Chemistry. 44: 2308-2318. PMID 11428925 DOI: 10.1021/Jm0010320 |
0.616 |
|
| 2001 |
Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT, Benbrook DM. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. Journal of the National Cancer Institute. 93: 516-25. PMID 11287445 DOI: 10.1093/Jnci/93.7.516 |
0.67 |
|
| 2000 |
Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, Ivey RT, Zacheis D, Brown CW, Nelson EC, Birckbichler PJ, Benbrook DM. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids Journal of Medicinal Chemistry. 43: 303. PMID 10650065 |
0.478 |
|
| 1999 |
Hurst RE, Waliszewski P, Waliszewska M, Bonner RB, Benbrook DM, Dar A, Hemstreet GP. Complexity, retinoid-responsive gene networks, and bladder carcinogenesis Advances in Experimental Medicine and Biology. 462: 449-467. PMID 10599447 DOI: 10.1007/978-1-4615-4737-2_35 |
0.377 |
|
| 1999 |
Zacheis D, Dhar A, Lu S, Madler MM, Klucik J, Brown CW, Liu S, Clement F, Subramanian S, Weerasekare GM, Berlin KD, Gold MA, Houck JR, Fountain KR, Benbrook DM. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. Journal of Medicinal Chemistry. 42: 4434-45. PMID 10543887 DOI: 10.1021/Jm990292I |
0.633 |
|
| 1999 |
Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, Ivey RT, Zacheis D, Brown CW, Nelson EC, Birckbichler PJ, Benbrook DM. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. Journal of Medicinal Chemistry. 42: 3602-14. PMID 10479291 DOI: 10.1021/Jm9900974 |
0.634 |
|
| 1999 |
Salsman S, Lu S, Benbrook DM. The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. Gynecologic Oncology. 73: 253-6. PMID 10329043 DOI: 10.1006/Gyno.1999.5352 |
0.603 |
|
| 1999 |
Waliszewski P, Waliszewska M, Gordon N, Hurst RE, Benbrook DM, Dhar A, Hemstreet GP. Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells Molecular and Cellular Endocrinology. 148: 55-65. PMID 10221771 DOI: 10.1016/S0303-7207(98)00235-4 |
0.36 |
|
| 1997 |
Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, Weerasekare GM, Gale JB, Patterson MK, Wang B, Wang W, Lu S, Rowland TC, DiSivestro P, Lindamood C, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. Journal of Medicinal Chemistry. 40: 3567-83. PMID 9357524 DOI: 10.1021/Jm970196M |
0.623 |
|
| 1997 |
Benbrook DM, Lu S, Flanagan C, Shen-Gunther J, Angros LH, Lightfoot SA. Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. Gynecologic Oncology. 66: 114-21. PMID 9234931 DOI: 10.1006/Gyno.1997.4736 |
0.63 |
|
| 1995 |
Benbrook DM, Rogers RS, Medlin MA, Dunn ST. Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. Tissue & Cell. 27: 269-74. PMID 7645007 DOI: 10.1016/S0040-8166(95)80047-6 |
0.344 |
|
| 1994 |
Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Molecular and Cellular Biology. 14: 7025-35. PMID 7935418 DOI: 10.1128/Mcb.14.10.7025 |
0.301 |
|
| 1988 |
Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature. 333: 669-72. PMID 2836738 DOI: 10.1038/333669A0 |
0.321 |
|
| Show low-probability matches. |